GlassScriptPhysician profile
Jennifer Lenzi
NPI 1194172684
$3,412.71
in general payments reported to CMS, 2019-2025
22 companies · $1,660 in 2025
The $1,660 reported for 2025 was more than what 93% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $271 · 2022: $94.97 · 2023: $219 · 2024: $1,167 · 2025: $1,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,968 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,967.91 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $953.21 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $851.77 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $311.20 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $196.07 | 2024-2025 | Dupixent |
| Haemonetics Corporation | $159.44 | 2025 | Teg6s Hemostasis System |
| Silk Road Medical, INC. | $123.26 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Verona Pharma, INC. | $115.05 | 2025 | Ohtuvayre |
| Lilly USA, LLC | $98.31 | 2025 | Zepbound |
| Mylan Specialty L.P. | $89.24 | 2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $79.98 | 2024-2025 | Aralast |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Philips North America LLC | $72.16 | 2024 | (Ak6) Vest Therapy |
| Pfizer INC. | $53.78 | 2024 | |
| Insmed, INC. | $52.89 | 2025 | Arikayce |
| Amgen INC. | $37.80 | 2025 | Tezspire |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $35.65 | 2024 | Xolair |
| Phadia US INC. | $18.70 | 2025 | Immunocap |
| Madrigal Pharmaceuticals | $18.64 | 2025 | Rezdiffra |
| Azurity Pharmaceuticals, INC. | $18.48 | 2025 | Alvesco |
| Viatris Specialty LLC | $17.18 | 2025 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $15.88 | 2024 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.03 | 2024 | Ofev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Lenzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.